Medtronic “Repurposes” Spine Convention Booth To Tell Its Side of BMP Story
This article was originally published in The Gray Sheet
The firm’s bare-bones booth at the North American Spine Society annual meeting was a conspicuous sign of strains between Medtronic and the clinical group over how issues surrounding its rhBMP-2 Infuse bone graft have been presented.
You may also be interested in...
FDA's Circulatory Systems Devices Panel will look at leadless pacemaker evidence needs; neurostim news from Nevro and Medtronic; BD and CareFusion hold hands; a Google-launched health tech firm gets a name; and more product and business updates.
The long-awaited independent analysis of clinical data on Medtronic’s InFuse recombinant human bone morphogenetic protein-2 (rhBMP-2) found no advantages to using it as a substitute for traditional bone grafts in spinal fusion surgery, while also revealing that the risks of rhBMP-2 may be greater than has been previously reported.
The March 26 special fraud alert reiterates the HHS watchdog’s “longstanding position that the opportunity for a referring physician to earn a profit, including through an investment in an entity for which he or she generates business, could constitute illegal remuneration under the anti-kickback statute.”